Full-Time
Market Manager
Surgiphor
Posted on 8/18/2026
Becton Dickinson
10,001+ employees
Global medical devices and diagnostics provider
Compensation Overview
$202.7k - $334.5k/yr
Florida, USA + 5 more
More locations: Philadelphia, PA, USA | Georgia, USA | Warwick, RI, USA | New York, NY, USA | New Jersey, USA
In Person
Field-based role requiring travel within the defined geographic area up to 75% of the time, including multiple overnight stays.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Becton Dickinson
See people who can refer or advise you
- A bachelor's degree in Business, Life Sciences, or a related field is required.
- A minimum of 5 years of sales experience is required, preferably in the medical device or medical technology industry.
- Experience with Surgical Wound Irrigation products is preferred, with 3 or more years documented.
- Ability to work respectfully in an Operating Room, tolerate observing surgeries, and stand for extended periods is required.
- Prior 1099 and/or IDN-level contracting experience is preferred.
- A documented history of meeting or exceeding sales targets is required.
- Familiarity with wound irrigation and infection prevention markets is required.
- Strong persuasion and influencing skills are required.
- Strong organizational and time-management skills are required.
- Ability to work independently, assume additional responsibilities, and balance priorities with minimal direction is required.
- Good judgment and professional behavior are required.
- Ability to build and sustain professional relationships with hospitals, sales personnel, and home-office personnel is required.
- Proficiency in Microsoft Office Suite is required.
- A criminal background satisfactory to BD must be possessed and maintained.
- Ability to meet and maintain customer and medical-facility access requirements, including periodic drug screenings with satisfactory results, is required.
- Vendor credentialing must be maintained.
- A valid state-issued driver's license and compliance with BD's auto-safety standards are required.
- Drive adoption, penetration, and market expansion of the Surgiphor portfolio across assigned strategic accounts and geographies.
- Serve as the Surgiphor product-line champion by providing clinical and commercial expertise and influencing surgeons, supply-chain leaders, and other stakeholders.
- Collaborate with 1099 distribution partners, National Accounts, Direct and Indirect Sales, Marketing, Professional Education, Medical Affairs, and internal sales teams.
- Maintain the Salesforce funnel and forecasting, including funnel roll-up from 1099 partners.
- Train 1099 representatives.
- Expand accounts beyond orthopedic or 1099-driven business and maintain existing non-1099-covered accounts.
- Develop thorough knowledge of the BD Surgiphor portfolio.
- Drive surgeon education in partnership with 1099 representatives and, where appropriate, the Medical Science Liaison team.
- Handle enterprise and top-down responsibilities tied to the Surgiphor portfolio.
- Attain sales goals and grow BD Surgiphor in the designated area.
- Educate key stakeholders on BD products and solutions as a product specialist.
- Develop new customers and establish and maintain customer relationships.
- Discuss products in relation to human anatomy.
- Develop and maintain relationships with Surgiphor key opinion leaders within the territory alongside the Medical Science Liaison team.
- Support national and regional symposia through sales, market research, and key opinion leader relationship development.
- Conduct product demonstrations, in-servicing, and training for clinical staff where applicable.
- Identify new business opportunities and implement strategic plans to expand market share.
- Attend on-label surgical procedures to provide technical support and ensure proper product usage.
- Collaborate with marketing, customer service, and medical affairs teams to meet customer needs and ensure product availability.
- Provide timely feedback on customer requirements and issues affecting the Surgical Wound Irrigation market.
- Provide frequent and timely verbal and written performance feedback related to business objectives and document sales metrics routinely in Salesforce.
- Monitor territory progress within the designated area to achieve and exceed annual sales goals.
- Manage the individual budget.
- Maintain compliance with BD's Quality Policy and documented quality processes and procedures.
- Report customer complaints according to BD complaint procedures.
- Conduct business in accordance with BD's Code of Ethics, BD Way, and applicable policies, rules, and procedures.
- Comply with BD Commercial Excellence management rigor in Salesforce.
- Perform special projects and other assigned duties.
- Prior 1099 and/or IDN-level contracting experience.
- Three or more years of documented sales experience with Surgical Wound Irrigation products.
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
- Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
- Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.
What critics are saying
- FDA classified BD’s intraosseous recall Class I on August 17, 2026.
- The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
- Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.
What makes Becton Dickinson unique
- BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
- BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
- BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 10%1 year growth
↑ 10%2 year growth
↑ 10%Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".
BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.
BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.